JDQ443
oral KRASG12C inhibitor ph. III candidate for NSCLC from de novo SBDD in SWII pocket Cancer Discov. Novartis, Basel, CH
Molecules of the Month - April 2022
oral KRASG12C inhibitor ph. III candidate for NSCLC from de novo SBDD in SWII pocket Cancer Discov. Novartis, Basel, CH
Molecules of the Month - April 2022